Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jan;35(1):10–13. doi: 10.1128/aac.35.1.10

Interaction of the antibiotic sparsomycin with the ribosome.

E Lazaro 1, A San Felix 1, L A van den Broek 1, H C Ottenheijm 1, J P Ballesta 1
PMCID: PMC244933  PMID: 2014963

Abstract

Phenol-alanine-sparsomycin, a derivative of sparsomycin carrying a p-hydroxy-benzyl function easily labeled by iodination, has been used to study the interaction of this drug with the ribosome. Our study indicated that the binding of the drug to the ribosome is sensitive to trichloracetic acid and is equally affected by disintegration of the particle after RNase and protease treatments. The ribosome is not irreversibly inactivated, and the chemical structure of the drug is not affected by interaction with the particle. These data are not compatible with the proposed covalent association of sparsomycin with the ribosome by G. A. Flynn and R. J. Ash (Biochem. Biophys. Res. Commun. 114:1-7, 1983); therefore, the antibiotic must inhibit protein synthesis through a reversible interaction with the ribosome.

Full text

PDF
10

Images in this article

13Image
on p.13

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cammarano P., Teichner A., Londei P., Acca M., Nicolaus B., Sanz J. L., Amils R. Insensitivity of archaebacterial ribosomes to protein synthesis inhibitors. Evolutionary implications. EMBO J. 1985 Mar;4(3):811–816. doi: 10.1002/j.1460-2075.1985.tb03702.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coutsogeorgopoulos C., Miller J. T., Hann D. M. Inhibitors of protein synthesis V. Irreversible interaction of antibiotics with an initiation complex. Nucleic Acids Res. 1975 Jul;2(7):1053–1072. doi: 10.1093/nar/2.7.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fernandez-Munoz R., Monro R. E., Torres-Pinedo R., Vazquez D. Substrate- and antibiotic-binding sites at the peptidyl-transferase centre of Escherichia coli ribosomes. Studies on the chloramphenicol. lincomycin and erythromycin sites. Eur J Biochem. 1971 Nov 11;23(1):185–193. doi: 10.1111/j.1432-1033.1971.tb01607.x. [DOI] [PubMed] [Google Scholar]
  4. Flynn G. A., Ash R. J. Necessity of the sulfoxide moiety for the biochemical and biological properties of an analog of sparsomycin. Biochem Biophys Res Commun. 1983 Jul 18;114(1):1–7. doi: 10.1016/0006-291x(83)91585-1. [DOI] [PubMed] [Google Scholar]
  5. Flynn G. A., Ash R. J. The chiral synthesis and biochemical properties of electron rich phenolic sulfoxide analogs of sparsomycin. Biochem Biophys Res Commun. 1990 Jan 30;166(2):673–680. doi: 10.1016/0006-291x(90)90862-h. [DOI] [PubMed] [Google Scholar]
  6. Gast F. U., Peters F., Pingoud A. The role of translocation in ribosomal accuracy. Translocation rates for cognate and noncognate aminoacyl- and peptidyl-tRNAs on Escherichia coli ribosomes. J Biol Chem. 1987 Sep 5;262(25):11920–11926. [PubMed] [Google Scholar]
  7. Monro R. E., Celma M. L., Vazquez D. Action of sparsomycin on ribosome-catalysed peptidyl transfer. Nature. 1969 Apr 26;222(5191):356–358. doi: 10.1038/222356a0. [DOI] [PubMed] [Google Scholar]
  8. Ottenheijm H. C., van den Broek L. A., Ballesta J. P., Zylicz Z. Chemical and biological aspects of sparsomycin, an antibiotic from Streptomyces. Prog Med Chem. 1986;23:219–268. doi: 10.1016/s0079-6468(08)70344-8. [DOI] [PubMed] [Google Scholar]
  9. Parfait R., Cocito C. Lasting damage to bacterial ribosomes by reversibly bound virginiamycin M. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5492–5496. doi: 10.1073/pnas.77.9.5492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pérez Gosalbez M., Rivera G. L., Ballesta J. P. Affinity labeling of peptidyl transferase center using the 3' terminal pentanucleotide from amino acyl-tRNA. Biochem Biophys Res Commun. 1983 Jun 29;113(3):941–947. doi: 10.1016/0006-291x(83)91089-6. [DOI] [PubMed] [Google Scholar]
  11. Tejedor F., Ballesta J. P. Iodination of biological samples without loss of functional activity. Anal Biochem. 1982 Nov 15;127(1):143–149. doi: 10.1016/0003-2697(82)90156-7. [DOI] [PubMed] [Google Scholar]
  12. van den Broek L. A., Liskamp R. M., Colstee J. H., Lelieveld P., Remacha M., Vázquez D., Ballesta J. P., Ottenheijm H. C. Structure-activity relationships of sparsomycin and its analogues. Inhibition of peptide bond formation in cell-free systems and of L1210 and bacterial cell growth. J Med Chem. 1987 Feb;30(2):325–333. doi: 10.1021/jm00385a014. [DOI] [PubMed] [Google Scholar]
  13. van den Broek L. A., Lázaro E., Zylicz Z., Fennis P. J., Missler F. A., Lelieveld P., Garzotto M., Wagener D. J., Ballesta J. P., Ottenheijm H. C. Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study. J Med Chem. 1989 Aug;32(8):2002–2015. doi: 10.1021/jm00128a051. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES